EconPapers    
Economics at your fingertips  
 

Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?

Jorge Mestre-Ferrandiz (), Néboa Zozaya, Bleric Alcalá and Álvaro Hidalgo-Vega
Additional contact information
Jorge Mestre-Ferrandiz: Independent Economics Consultant
Néboa Zozaya: Weber Economía y Salud
Bleric Alcalá: Weber Economía y Salud
Álvaro Hidalgo-Vega: Fundación Weber, Majadahonda

PharmacoEconomics, 2018, vol. 36, issue 12, 1407-1420

Abstract: Abstract For medicines with different valued indications (uses), multi-indication pricing implies charging different prices for different uses. In this article, we assess how multi-indication pricing could help achieve overall strategic objectives of pricing controls, summarise its advantages and disadvantages (vs. uniform pricing) and estimate the hypothetical impact on prices of moving towards multi-indication pricing for specific oncologic medicines in Spain. International experience shows that multi-indication pricing can be implemented in real practice, and indeed a few initiatives are currently in use, albeit mostly applied indirectly through confidential pricing agreements that offer a way to discriminate prices across countries without altering list prices. However, some more sophisticated systems are in place in Italy, and more recently in Spain, where the objective is to monitor usage per patient/indication, and ultimately pay for outcomes. Based on the existing experience, we also outline six conditions required for multi-indication pricing. Multi-indication pricing is a useful tool to determine the relative prices of a drug for multiple (different-valued) indications, but by itself will not offer the ‘solution’ to what the absolute price should be. That will be driven, among other things, by cost-effectiveness thresholds, if they exist. Overall, we argue multi-indication pricing is nice in theory and it could work in practice, although changes in the manner in which medicines are priced, procured and monitored in clinical practice need to be applied.

Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed

Downloads: (external link)
http://link.springer.com/10.1007/s40273-018-0716-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:36:y:2018:i:12:d:10.1007_s40273-018-0716-4

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla ().

 
Page updated 2019-11-06
Handle: RePEc:spr:pharme:v:36:y:2018:i:12:d:10.1007_s40273-018-0716-4